ArticleOncogene2006
Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- FYB1-targeted modulation of CAPG promotes AML progression.Molecular and cellular biochemistry · 2025Article
- Increased CAPG inhibits ferroptosis to drive tumor proliferation and sorafenib resistance in hepatocellular carcinoma via the WDR74-p53-SLC7A11 pathway.International journal of biological sciences · 2025Article
- Super-enhancer-associated gene CAPG promotes AML progression.Communications biology · 2023Article
- CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK.World journal of surgical oncology · 2022Article
- Preclinical evaluation of an unconventional ruthenium-gold-based chemotherapeutic: RANCE-1, in clear cell renal cell carcinoma.Cancer medicine · 2019Article
- CapG promotes resistance to paclitaxel in breast cancer through transactivation of PIK3R1/P50.Theranostics · 2019Article
- Novel mediators of breast cancer bone metastasis-insights from studies of gene-regulation and the global proteome.Annals of translational medicine · 2018Article
- CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.Theranostics · 2018Article
- Capping Actin Protein Overexpression in Human Colorectal Carcinoma and Its Contributed Tumor Migration.Analytical cellular pathology (Amsterdam) · 2018Article
- Function of the macrophage-capping protein in colorectal carcinoma.Oncology letters · 2017Article
- Molecular mechanisms of breast cancer metastasis by gene expression profile analysis.Molecular medicine reports · 2017Article
- Chromatin interactions and candidate genes at ten prostate cancer risk loci.Scientific reports · 2016Article
- Parasitic nematode-induced CD4+Foxp3+T cells can ameliorate allergic airway inflammation.PLoS neglected tropical diseases · 2014Article
- Epigenomic alterations in localized and advanced prostate cancer.Neoplasia (New York, N.Y.) · 2013Article
- Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.The American journal of pathology · 2009Article
- Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer.Molecular & cellular proteomics : MCP · 2009Article
- Supervillin reorganizes the actin cytoskeleton and increases invadopodial efficiency.Molecular biology of the cell · 2009Article
- Article
- Response projected clustering for direct association with physiological and clinical response data.BMC bioinformatics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previously, we isolated a series of cell lines from a human diploid fibroblast lineage as a model for multistep tumorigenesis in humans. After passaging a single LT-transfected fibroblast clone, differently progressed cell lines were obtained, including immortalized, anchorage-independent and tumorigenic cell lines. In the present paper, we analysed the gene expression profiles of these model cell lines, and observed that expression of the CapG protein was lost in the tumorigenic cell line. To examine the possibility that loss of CapG protein expression was required for tumorigenic progression, we transfected CapG cDNA into the tumorigenic cell line and tested for tumor-forming ability in nude mice. Results showed that ectopic expression of CapG suppressed tumorigenicity, but not growth in soft agar or liquid medium. We also found that certain cancer cell lines including stomach cancer, lung cancer and melanoma had also lost CapG expression. One such cancer cell line AZ521 also became non-tumorigenic after the introduction of CapG cDNA. Moreover, we showed that CapG expression was repressed in small-cell lung cancer tissues. Together, our findings indicated that CapG is a new tumor suppressor gene involved in the tumorigenic progression of certain cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.